NEFFY Drug Patent Profile

Which patents cover Neffy, and when can generic versions of Neffy launch?

Neffy is a drug marketed by Ars Pharms Operation and is included in one NDA. There are eight patents protecting this drug and two Paragraph IV challenges.

This drug has eighty-four patent family members in thirty-three countries.

The generic ingredient in NEFFY is epinephrine. There are twenty-one drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Neffy

A generic version of NEFFY was approved as epinephrine by BPI LABS on July 29^th, 2014.

Summary for NEFFY

International Patents:	84
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Patent Applications:	4,084
Drug Prices:	Drug price information for NEFFY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEFFY
What excipients (inactive ingredients) are in NEFFY?	NEFFY excipients list
DailyMed Link:	NEFFY at DailyMed

See drug prices for NEFFY

Pharmacology for NEFFY

Drug Class	Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists

Paragraph IV (Patent) Challenges for NEFFY

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEFFY	Nasal Spray	epinephrine	1 mg/spray	214697	1	2025-12-29
NEFFY	Nasal Spray	epinephrine	2 mg/spray	214697	1	2025-06-30

US Patents and Regulatory Information for NEFFY

NEFFY is protected by eight US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ars Pharms Operation	NEFFY	epinephrine	SPRAY;NASAL	214697-002	Mar 5, 2025		RX	Yes	Yes
Ars Pharms Operation	NEFFY	epinephrine	SPRAY;NASAL	214697-002	Mar 5, 2025		RX	Yes	Yes			Y
Ars Pharms Operation	NEFFY	epinephrine	SPRAY;NASAL	214697-002	Mar 5, 2025		RX	Yes	Yes			Y
Ars Pharms Operation	NEFFY	epinephrine	SPRAY;NASAL	214697-001	Aug 9, 2024		RX	Yes	Yes			Y
Ars Pharms Operation	NEFFY	epinephrine	SPRAY;NASAL	214697-002	Mar 5, 2025		RX	Yes	Yes			Y

International Patents for NEFFY

See the table below for patents covering NEFFY around the world.

Country	Patent Number	Title	Estimated Expiration
United Kingdom	2587934
Japan	5752048
Canada	2748268	COMPOSITIONS POUR ADMINISTRATION DE MEDICAMENTS (COMPOSITIONS FOR DRUG ADMINISTRATION)
Australia	2021254650
China	116549389	鼻内肾上腺素制剂及治疗疾病的方法 (Intranasal epinephrine formulations and methods of treating diseases)

Supplementary Protection Certificates for NEFFY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3678649	122025000010	Germany		PRODUCT NAME: KOMBINATION AUS EPINEPHRIN AND DODECYLMALTOSID, IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/24/1846 20240822
3678649	301317	Netherlands		PRODUCT NAME: COMBINATIE VAN EPINEFRINE OF EEN ZOUT DAARVAN, EN DODECYLMALTOSIDE; REGISTRATION NO/DATE: EU1/24/1846 20240823
3678649	PA2025507	Lithuania		PRODUCT NAME: VISU FORMU EPINEFRINO IR DODECILMALTOZIDO DERINYS SAUGOMASPAGRINDINIO PATENTO; REGISTRATION NO/DATE: EU/1/24/1846 20240822
3678649	LUC00378	Luxembourg		PRODUCT NAME: COMBINAISON D'EPINEPHRINE ET DE DODECYLMALTOSIDE, SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/24/1846 20250211
3678649	C20250011	Finland

NEFFY: Market Dynamics and Financial Trajectory

Last updated: May 4, 2026

What is NEFFY’s market position and who drives demand?

NEFFY is an intranasal formulation of epinephrine for the treatment of severe allergic reactions (anaphylaxis). Demand is driven by three adoption vectors: (1) household and school use of at-home emergency kits, (2) physician and allergist prescribing patterns for patients at risk of anaphylaxis, and (3) institutional buying where intranasal delivery can reduce injection friction.

Key market dynamics shaping NEFFY’s trajectory:

• Route-of-administration advantage: Intranasal epinephrine can lower barriers versus autoinjectors for some patient groups and caregivers (needle aversion, dexterity limitations, immediate administration before EMS).
• Usage setting expansion: Adoption grows when products are included in emergency action plans for schools, camps, and workplaces.
• Competitive substitution: NEFFY competes against intramuscular epinephrine delivery options (especially autoinjector brands) on ease-of-use and user preference rather than on efficacy alone, since guidelines often prioritize rapid administration.

How does NEFFY fit into the anaphylaxis therapeutics landscape?

NEFFY’s commercial logic is anchored in the anaphylaxis epinephrine standard: rapid epinephrine administration is the core intervention, and route selection affects real-world speed and likelihood of use.

Competitive frame

• Standard of care in community settings is rapid epinephrine administration.
• Autoinjectors have entrenched distribution, pharmacy familiarity, and patient training programs.
• Intranasal epinephrine is positioned as simpler to deliver quickly without needle use, which matters in first response by non-medical caregivers.

What financial trajectory has NEFFY shown so far?

No complete financial trajectory can be stated from the information provided in the prompt. A precise market and earnings path for NEFFY requires revenue disclosures, channel mix, sell-through/sell-in trends, net sales by geography, and guidance updates from the sponsor and distributor partners. Without those data points, a complete and accurate financial trajectory cannot be produced.

What market signals should be tracked to forecast NEFFY’s next phase?

For NEFFY, the leading indicators that typically explain adoption and revenue momentum are:

1. Prescription and NRx conversion

   • New-to-brand prescriptions in allergy and primary care.
   • Refill behavior among previously diagnosed anaphylaxis-risk patients.

2. Formulary and payer coverage

   • Prior authorization frequency and coverage tiering.
   • Preferred status and exclusions in key commercial formularies.

3. Institutional contracting

   • School and camp emergency kits adoption.
   • Clinic and urgent care inventory placement.

4. Channel inventory and returns

   • Sell-in versus sell-through divergence.
   • Reorder cadence reflecting actual consumption.

5. Regulatory and label-driven expansion

   • Any label additions that expand eligible patient populations.
   • Safety updates that affect clinician comfort and patient uptake.

What are the cost and reimbursement dynamics that determine adoption speed?

Intranasal epinephrine uptake depends on payer economics in two ways:

• Patient out-of-pocket cost controls household purchase and adherence in high-frequency renewal cycles.
• Coverage constraints (PA, step therapy, quantity limits) directly affect brand switching and persistence.

Because NEFFY is a rescue medication, payer policies that impact access can create sudden shifts in demand when coverage changes.

Key drivers of near-term growth versus headwinds

Near-term growth drivers

• Needle-avoidance and caregiver usability benefits that increase actual administration likelihood.
• Scaling of awareness among allergists, school health networks, and primary care.

Headwinds

• Autoinjector market inertia and clinician familiarity.
• Payer constraints that slow conversion from initial prescriptions to sustained refills.
• Training and workflow integration (ensuring users know when and how to administer intranasally and when to seek emergency care).

Market dynamics summary table

Dimension	What moves the needle for NEFFY	Primary mechanism
Household adoption	Patient and caregiver willingness to use intranasal epinephrine	Reduced delivery friction
Physician prescribing	Confidence in intranasal delivery for anaphylaxis-risk patients	Guideline alignment and experience
Institutional buying	Ease of stock management and administration	Lower perceived operational risk
Payer access	Coverage tier and PA outcomes	Patient access and persistence
Competitive substitution	Speed of switching from autoinjectors	Real-world preference and coverage

Key Takeaways

• NEFFY’s market position is built on intranasal usability for anaphylaxis rescue, where caregiver and non-medical administration speed can determine real-world uptake.
• Adoption is shaped by prescribing behavior, payer coverage, and institutional contracting for emergency action planning.
• A complete, accurate financial trajectory cannot be produced from the provided prompt; revenue and guidance trend data are required to quantify NEFFY’s market monetization path.

FAQs

1. What type of drug is NEFFY?
   NEFFY is intranasal epinephrine for treatment of severe allergic reactions (anaphylaxis).

2. What determines NEFFY’s sales growth most directly?
   Prescription conversion, payer coverage access, and institutional placement that supports repeat availability for at-risk individuals.

3. How does NEFFY compete against autoinjectors?
   It competes on ease of administration and caregiver usability, aiming to improve likelihood of immediate epinephrine delivery.

4. What reimbursement factors can slow or accelerate NEFFY uptake?
   Prior authorization requirements, formulary tier placement, and patient cost-sharing that influence purchase and refills.

5. What leading indicators should forecast NEFFY momentum?
   NRx trends, sell-through versus sell-in, reorder cadence from key channels, and changes in payer coverage behavior.

---

References

[1] FDA. Label and prescribing information for NEFFY (as available on FDA’s product pages).